Adjuvant Therapy
搜索文档
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
Businesswire· 2026-02-28 23:05
核心观点 - 默沙东宣布其KEYTRUDA与WEL组合作为辅助疗法，相比KEYTRUDA单药治疗，降低了特定早期肾细胞癌患者的疾病复发或死亡风险 [1] 临床研究结果 - 在特定早期肾细胞癌患者中，KEYTRUDA与WEL组合疗法作为辅助治疗，相比KEYTRUDA单药，降低了疾病复发或死亡的风险 [1]
